Alnylam trades partner Sanofi for Regeneron in $800M deal

Cambridge gene therapy firm Alnylam is changing alliances, cutting research ties with longtime partner Sanofi and teaming up with Regeneron on new eye and central nervous system treatments.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.